TICKERNERD
Menu
EQEQHealthcare · Biotechnology

EQ Stock Forecast: Equillium, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.42
0.00% on the day

The 9 Wall Street analysts covering Equillium, Inc. hold a median 12-month price target of $7 — +393.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$90.0M
Ticker Nerd rank
37/ 100
Median analyst target
$7.00
Analysts covering
9
Revenue$0.0
Operating income−$5.2M
Net income−$4.7M
Free cash flow−$4.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.8%
1M
−12.3%
YTD
−8.4%
1Y
+3.6%
From 52W high
−55.6%
From 52W low
+69.0%
$0.84
$3.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EQ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
37/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
75
Momentum
69
Revisions
63
Value
27
Quality
20
Issuance
19
Accruals
19
Volatility
16

Growth (86): Sales and profits are climbing, and climbing faster than before.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EQ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26EQHigh $20.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $4.00Median $7.00High $20.00

The green dot is the last close — the median target sits +393.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026Leerink PartnersAssumesOutperform$6.00
4 Sept 2026Roth CapitalReiteratesBuy—
4 Sept 2026Roth CapitalReiteratesBuy$12
13 July 2026Piper SandlerInitiatesOverweight$20
13 July 2026Piper SandlerInitiatesOverweight—
2 June 2026Roth CapitalReiteratesBuy—
28 May 2026Leerink PartnersUpgradeOutperform—
28 May 2026Roth CapitalReiteratesBuy—
17 Apr 2026Roth CapitalReiteratesBuy—
16 Apr 2026B. Riley SecuritiesInitiatesBuy—
14 Apr 2026Raymond JamesInitiatesStrong Buy—
13 Mar 2026Roth CapitalInitiatesBuy—
28 Mar 2025Leerink PartnersDowngradeMarket Perform—
1 Nov 2024Jones TradingDowngradeHold—
19 Aug 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
26 Dec 2023HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EQ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EQ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Equillium, Inc. returned +3.6% against +13.1% for the S&P 500, dividends included.

EQ vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26EQS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EQ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Equillium, Inc. (EQ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.7×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
1.6×

Cheaper than 51% of US stocks

EV / EBITDA
−1.7×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−34.0%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Equillium, Inc. (EQ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Equillium, Inc. has a market value of $90.0M and an enterprise value of $33.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.0M.

  • Diluted earnings per share, trailing twelve months: $−0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$20.1M.

  • Shares outstanding: 63.4M.

  • Trailing P/E: −3.7×; forward P/E: −5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Equillium, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

EQ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EQEquillium, Inc.$90.0M37
CNXUConexeu Sciences, Inc.$88.8M1
TNYATenaya Therapeutics, Inc.$92.0M35
TNXPTonix Pharmaceuticals Holding Corp.$92.1M32
NTHINeOnc Technologies Holdings, Inc.$87.3M20
ATRAAtara Biotherapeutics, Inc.$86.9M58
NRXSNeurAxis, Inc.$93.7M67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EQ news & analysis

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

GlobeNewsWire · 26 Oct 2026positive

Equillium announced that the first subject has been dosed in its Phase 1 trial of EQ504 in Australia. The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics; topline proof-of-mechanism data are anticipated in Q2 2027.

Why it matters — The first dosing marks the trial’s start and triggers the closing of an additional $20 million in funding, which the company expects to support currently planned operations into 2029.

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

GlobeNewsWire · 6 Oct 2026positive

Equillium announced a poster presentation at the 50th Anniversary La Jolla Immunology Conference featuring new preclinical data on EQ504. The data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation.

Why it matters — The presentation offers EQ watchers additional information about EQ504’s preclinical profile in intestinal inflammation.

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

GlobeNewsWire · 5 Oct 2026positive

Equillium received Australian regulatory clearance to begin a first-in-human clinical trial of EQ504, with dosing expected to start by early November 2026 and topline Phase 1 proof-of-mechanism data anticipated about six months after study initiation.

Why it matters — This regulatory clearance advances EQ504 into the clinic and provides a timeline for early proof-of-mechanism data that EQ investors may follow.

Equillium Announces Poster Presentations at the 7th International AHR Conference

GlobeNewsWire · 29 Sept 2026neutral

Equillium announced poster presentations at the 7th International AHR Conference. The new preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation.

Why it matters — The poster presentations highlight new preclinical findings on EQ504, offering EQ watchers deeper insight into the candidate's mechanism of action.

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

MarketBeat · 27 Sept 2026neutral

Equillium's Chief Scientific Officer Stephen Connelly discussed the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, in a fireside chat. He outlined plans for a potential Phase I start for the ulcerative colitis drug EQ504 in the fourth quarter.

Why it matters — EQ watchers would be interested in the company's stated pipeline timeline for EQ504 as it indicates progress toward a planned Phase I study.

FAQ

Frequently asked questions about EQ stock

What is the EQ stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Equillium, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EQ stock a buy right now?

Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 37 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EQ?

As at 28 Oct 2026, Equillium, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will EQ stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +393.0% from the last close, and Ticker Nerd's factor model ranks Equillium, Inc. 37 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EQ stock forecast for 2030?

No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.

How has EQ stock performed over the past year?

Equillium, Inc. returned +3.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Equillium, Inc. do?

Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need.

What is the latest news on EQ?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504". Equillium announced that the first subject has been dosed in its Phase 1 trial of EQ504 in Australia. The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics; topline proof-of-mechanism data are anticipated in Q2 2027.

Company

About Equillium, Inc.

Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.

CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com